Medicus Pharma Ltd (MDCX)
NASDAQ (CM) NASDAQ (CM) Primary 
Medicus Pharma expands basal cell carcinoma study after encouraging early data
Medicus Pharma (NASDAQ:MDCX) said it has received approval from an Institutional Review Board (IRB) to increase the number of participants in its ongoing Phase 2 clinical trial of a novel non-invasive treatment for basal cell carcinoma (BCC), the most common form of skin cancer. The company will raise the trial's enrollment target to 90 patients from 60 and expand the study beyond the current nine clinical sites in the United States to additional US locations and two in Europe.
Medicus Pharma CEO discusses latest skin cancer trial results - ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the latest progress in the company's ongoing clinical trials for its innovative skin cancer treatment. The company is developing a non-invasive microneedle-based therapy designed to treat basal cell carcinoma by delivering doxorubicin directly to the lesion site.
Medicus Pharma unveils pricing of financing to advance skin cancer treatment
Medicus Pharma (NASDAQ:MDCX) has announced the pricing of its Tier II Regulation A offering, aiming to raise approximately $4.2 million through the sale of 1.49 million units at $2.80 per unit. Each unit includes one common share and one warrant, with the warrants exercisable at $2.80 per share for a five-year period.
Medicus Pharma's Phase 2 skin cancer trial hits key milestone - ICYMI
Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) CEO Dr Raza Bokhari talked with Proactive about the company's ongoing Phase 2 clinical study for its lead asset, SKNJCT. This novel, noninvasive treatment is designed to deliver doxorubicin directly to basal cell carcinoma lesions.
Medicus Pharma expects interim data from Phase 2 skin cancer trial by quarter-end
Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) has announced progress in its Phase 2 clinical study SKNJCT-003, which is evaluating its investigational drug D-MNA in basal cell carcinoma (BCC). The company said that the trial, currently underway at nine clinical sites in the United States, has now randomized more than 50% of the 60 patients expected to be enrolled.
Medicus Pharma announces equity deal, shifts focus to Nasdaq
Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) announced that it has entered into a Standby Equity Purchase Agreement with YA II PN, an investment fund managed by Yorkville Advisors Global, to sell up to US$15 million of its shares over 36 months. The investor's purchase of shares under the agreement is subject to SEC approval of a resale registration statement.
Medicus Pharma CEO charts course for 2025 with clinical milestones for SkinJect
Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX), a biotechnology company specializing in non-invasive dermatological treatments, is gearing up for a pivotal year in 2025. The company is advancing SkinJect, its flagship asset for basal cell carcinoma, while planning significant expansions to its drug pipeline.
Medicus Pharma achieves FDA MUMS approval for equine squamous cell carcinoma patch - ICYMI
Earlier this week Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) announced that its innovative skin patch treatment has received Minor Use and Minor Species (MUMS) designation from the FDA. The patch, which uses a cellulose-based, doxorubicin-loaded design, is aimed at treating squamous cell carcinoma in horses.
Medicus Pharma's horse skin cancer treatment wins MUMS designation from FDA
Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) announced that the Food and Drug Administration has granted Minor Use in Major Species (MUMS) designation for its Investigational New Animal Drug, a dissolvable Doxorubicin-containing microneedle array (D-MNA) patch targeting external squamous cell carcinoma in horses. The MUMS designation, akin to the Orphan Drug status for human medicine, provides Medicus with a seven-year exclusive marketing period following product approval or conditional approval, contingent on meeting the program's requirements.
Medicus Pharma CEO on basal-cell carcinoma trial progress – ICYMI
Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) provided an update on its phase two clinical trial for a novel non-invasive treatment targeting basal-cell carcinoma. CEO Raza Bokhari told Proactive that 25% of patient recruitment for the U.S.-based trial has been completed.
Medicus Pharma eyes pivotal trial for novel skin cancer therapy as Phase 2 enrollment progresses
Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) announced that its Phase 2 clinical study targeting basal cell carcinoma (BCC) is now being conducted at nine clinical sites across the United States, with more than 25% of the 60 patients expected to be enrolled in the study already randomized. An interim data analysis is planned for Q1 2025, and Medicus intends to submit these findings to the US Food and Drug Administration (FDA) to request a Type C meeting in Q2 2025, the company said on Monday.
Medicus Pharma partners with Swanielle to expand basal cell carcinoma study into Asia-Pacific
Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) announced it has entered into an agreement with healthcare consulting firm Swanielle to explore expanding its Phase 2 clinical study for treating Basal Cell Carcinoma (BCC) into the Asia-Pacific region. The collaboration aims to identify potential pharmaceutical or biotech partners in Southeast Asia to facilitate this expansion.
